Atorvastatin hemicalcium

A competitive inhibitor of HMG-CoA reductase (HMGCR) that acts as a lipid-lowering agent for prevention of events associated with cardiovascular disease.Dyslipidemia Approved (In Vitro) :Atorvastatin treatment decreases apoptosis of myocardial cells by down-regulating GRP78, caspase-12 and CHOP expression in myocardial cells after myocardial infarction, and the endoplasmic reticulum (ER) stress is activated in response to heart failure and angiotensin II (Ang II) stimulation. (In Vivo) :Atorvastatin (20-30 mg/kg; oral gavage; once a day; for 28 days; ApoE / mice) treatment significantly reduces endoplasmic reticulum (ER) stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE-/- mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1β are all remarkably inhibited after Atorvastatin treatment.

Product Specifications

CAS Number

134523-03-8

Product Name Alternative

Atorvastatin hemicalcium

Field of Research

Pharmacology & Drug Discovery

Purity

>98% (HPLC)

Solubility

10 mM in DMSO

Smiles

CC (C) C1=C (C (=C (N1CC[C@H] (C[C@H] (CC (=O) [O-]) O) O) C2=CC=C (C=C2) F) C3=CC=CC=C3) C (=O) NC4=CC=CC=C4.CC (C) C1=C (C (=C (N1CC[C@H] (C[C@H] (CC (=O) [O-]) O) O) C2=CC=C (C=C2) F) C3=CC=CC=C3) C (=O) NC4=CC=CC=C4.[Ca+2]

Molecular Formula

C33H34FN2O5-

Molecular Weight

557.6324

Storage Conditions

Storage temperature: -20°C. Stability: ≥ 2 years

Notes

For research use only.

Other Product Names

1H-Pyrrole-1-heptanoic acid, 2- (4-fluorophenyl) -β, δ-dihydroxy-5- (1-methylethyl) -3-phenyl-4-[ (phenylamino) carbonyl]-, calcium salt (2:1), (βR, δR) -